PointCheck™
Screening for severe neutropenia (low white blood cells)
Pre-clinical/Clinical ValidationActive
Key Facts
Indication
Screening for severe neutropenia (low white blood cells)
Phase
Pre-clinical/Clinical Validation
Status
Active
Company
About Leuko
Leuko is a Barcelona-based medtech startup, founded in 2017 as a spin-out from MIT, focused on non-invasive blood cell monitoring. Its flagship product, PointCheck™, is a portable, at-home device designed to screen for severe neutropenia (dangerously low white blood cells) by imaging capillaries in the finger, eliminating the need for blood draws. The company aims to improve quality of life and clinical outcomes for chemotherapy patients by enabling frequent monitoring and early intervention. Leuko is in the development and clinical validation stage, having won several awards and secured non-dilutive funding, but its device remains investigational and pre-commercial.
View full company profile